Physician

Mohammad P Rahman, M.D.

According to 2025 Medicare claims, Mohammad Rahman, M.D. (NPI: 1952375578) practices medical oncology in the Weirton-Steubenville, WV-OH market, with the plurality of this provider's patient population coming from Jefferson, OH. This provider's primary affiliated billing organization is ONCOLOGY HEMATOLOGY ASSOCIATION INC (NPI: 1861469223; TIN: 251762980) and primary practice location at 43952-2300. Rahman is affiliated with the ACO West Virginia (ACO ID: A3563), participating under the MSSP model.

Rahman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 476 traditional Medicare patients, billed 1,844 HCPCS/CPT codes, and received $122,609 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,641 prescription claims across 336 beneficiaries totaling $3,994,378 in drug costs, led by Ibrance (Palbociclib). DME data shows 11 claims. Open Payments data shows 24 records totaling $1,644. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $78,517 and ending at $122,609. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,654,122 to $3,994,378. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,424 to $1,479.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	625	1,565	$78,517
2016	556	1,870	$112,267
2017	582	1,877	$144,755
2018	559	1,475	$109,125
2019	498	1,592	$122,086
2020	488	1,307	$88,359
2021	496	1,275	$119,173
2022	452	1,170	$97,637
2023	504	1,247	$101,077
2024	476	1,844	$122,609

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	294	1,849	$1,654,122
2016	328	1,993	$2,087,548
2017	308	1,599	$2,112,874
2018	279	1,444	$3,167,639
2019	247	1,352	$3,296,996
2020	258	1,470	$2,813,010
2021	283	1,629	$4,275,309
2022	260	1,467	$3,824,838
2023	290	1,567	$4,200,864
2024	336	1,641	$3,994,378

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	201	$49,220
2016	N/R	131	$20,603
2017	N/R	132	$14,314
2018	N/R	61	$4,967
2019	N/R	46	$3,940
2020	N/R	16	$2,898
2021	N/R	16	$2,878
2022	N/R	N/R	N/R
2023	N/R	38	$9,080
2024	N/R	11	$138

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	75	110	$131
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	272	560	$105
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	160	180	$63
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	87	94	$39
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	351	604	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	75	2,044	$1,145,389
Pomalyst	Pomalidomide	25	595	$473,411
Promacta	Eltrombopag Olamine	38	1,114	$346,365
Jakafi	Ruxolitinib Phosphate	19	570	$323,047
Calquence	Acalabrutinib Maleate	18	540	$272,042

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$138

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	24	$1,644	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mohammad P. Rahman, M.D.?

Tedicare shows public-source Medicare data for Mohammad P. Rahman, M.D. (NPI 1952375578), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mohammad P. Rahman, M.D. have ACO affiliation data?

Mohammad P. Rahman, M.D. is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563).

What billing organization is linked to Mohammad P. Rahman, M.D.?

Mohammad P. Rahman, M.D. is linked to ONCOLOGY HEMATOLOGY ASSOCIATION INC (billing NPI 1861469223) in the available physician profile data.

Does Mohammad P. Rahman, M.D. have Open Payments data?

Mohammad P. Rahman, M.D. has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.